About

About Droplet Biosciences Droplet Biosciences focused on the diagnostic and therapeutic utility of lymphatic fluid and is currently developing ultra-sensitive liquid-biopsy assays to detect molecular residual disease (MRD) across a range of cancers. Leveraging standard, powerful molecular diagnostic technologies and proprietary assay design, the company aims to provide clinicians with actionable information earlier than conventional methods, enabling adjuvant therapy decisions and improving patient outcomes.